Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | ARG1 | P05089 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6491730 | 0.98 | GABRA5 (0.37) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL30948840 | 0.88 | KDM4E (0.38) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| Hydrochloric Acid SCHEMBL17560334 | 0.86 | KDM4E (0.37) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL4734231 | 0.84 | — | — | |
| SCHEMBL8873859 | 0.80 | GABRA5 (0.44) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL12928717 | 0.80 | GABRA5 (0.39) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL17818902 | 0.79 | EPHX1 (0.38) | EPHX1KMT2ALMNAMEN1 | |
| SCHEMBL30277414 | 0.79 | EPHX1 (0.33) | EPHX1KMT2ALMNAMEN1 | |
| Hydrochloric Acid SCHEMBL6824935 | 0.78 | GABRA5 (0.43) | GABRA5GABRB2GABRA1GABRA4TSHR | |
| SCHEMBL8283504 | 0.77 | EPHX1 (0.38) | EPHX1KMT2ALMNAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117642385-A | Pesticidally active cyclic amine compounds | 先正达农作物保护股份公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| CN-101668769-B | Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors | AETERNA ZENTARIS GMBH | 2014-07-02 | — | — | CN | disclosed |
| CN-101835779-B | Purine derivatives useful as PI3 kinase inhibitors | HOFFMANN LA ROCHE | 2014-01-29 | — | — | CN | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| CN-101835779-A | Purine derivative as the PI3 kinase inhibitor | HOFFMANN LA ROCHE | 2010-09-15 | — | — | CN | disclosed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| CN-101668769-A | Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors | AETERNA ZENTARIS GMBH | 2010-03-10 | — | — | CN | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| EP-1165528-B1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-09-01 | — | — | EP | disclosed |
| EP-1165528-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| EP-1150970-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Sanofi-Aventis (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000058292-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000047572-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI-SYNTHELABO (FR) | 2000-08-17 | — | — | WO | disclosed |
| US-5614534-A | Derivatives of β, β-dimethyl-4-piperidineethanamine as inhibitors of the cholesterol biosynthesis | FOURNIER INDUSTRIE ET SANTE (FR) | 1997-03-25 | — | — | US | disclosed |
| EP-0699187-B1 | BETA,BETA-DIMETHYL-4-PIPERIDINEETHANAMINE DERIVATIVES AS INHIBITORS OF THE CHOLESTEROL BIOSYNTHESIS | FOURNIER IND & SANTE (FR) | 1997-01-22 | — | — | EP | disclosed |
| EP-0699187-A1 | DERIVATIVES OF -g(b), -g(b)-DIMETHYL-4-PIPERIDINEETHANAMINE AS INHIBITORS OF THE CHOLESTEROL BIOSYNTHESIS | FOURNIER IND & SANTE (FR) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994026713-A1 | DERIVATIVES OF β, β-DIMETHYL-4-PIPERIDINEETHANAMINE AS INHIBITORS OF THE CHOLESTEROL BIOSYNTHESIS | FOURNIER INDUSTRIE ET SANTE (FR) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | GABRA5 3335/4885GABRB2 3137/4885GABRA1 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.